Loading clinical trials...
Loading clinical trials...
Use of Warfarin After the First Trimester in Pregnant Women With Antiphospholipid Syndrome
Evaluation of shifting to oral vitamin K antagonist after the first trimester instead of using low molecular weight heparin (LMWH) throughout pregnancy in pregnant women with antiphospholipid syndrome (APS)
Women will be randomly divided into two groups; one will be subjected to anticoagulant therapy by Enoxaparin throughout pregnancy and the other will be subjected to anticoagulant therapy by Enoxaparin in the first trimester then Warfarin after the first trimester until termination of pregnancy.
Age
20 - 38 years
Sex
FEMALE
Healthy Volunteers
No
Obstetrics and Gynecology Department in Mansoura University Hospital
Al Mansurah, Dakahlia Governorate, Egypt
Private practice settings
Al Mansurah, Dakahlia Governorate, Egypt
Start Date
November 1, 2014
Primary Completion Date
December 1, 2024
Completion Date
June 1, 2025
Last Updated
October 31, 2023
100
ESTIMATED participants
Enoxaparin
DRUG
Warfarin
DRUG
Lead Sponsor
Mohamed Sayed Abdelhafez
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT00616317